Ensifentrine 3 mg per 2.5 mL Suppliers & Bulk Manufacturers

Available Forms: Inhalation solution

Available Strengths: 3 mg per 2.5 mL

Reference Brands: Ohtuvayre (USA)

Category: Respiratory Disorder

Ensifentrine is a nebulised maintenance treatment for chronic obstructive pulmonary disease (COPD), the first to block both PDE3 and PDE4, which relaxes the airways and reduces inflammation. It was approved in the US in 2024 as Ohtuvayre and is still a patented innovator product. Supply is through authorised distribution or named-patient import; ask us which route fits your country.

Product Description:

Ensifentrine is an inhaled medication used for the maintenance treatment of chronic obstructive pulmonary disease (COPD) in adults. It is marketed under the brand name Ohtuvayre and represents a novel therapeutic approach by combining dual inhibition of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) in a single molecule. This dual mechanism allows ensifentrine to deliver both bronchodilator and anti-inflammatory effects, addressing key pathological features of COPD.

As a PDE3 inhibitor, ensifentrine helps relax airway smooth muscle, leading to bronchodilation and improved airflow. At the same time, its PDE4 inhibitory activity reduces airway inflammation, which contributes to symptom control and disease management. Ensifentrine is administered by inhalation, allowing targeted delivery directly to the lungs and minimizing systemic exposure.

Ensifentrine is indicated for long-term COPD management and is used to improve lung function and reduce respiratory symptoms. Its inhaled formulation makes it suitable for patients who require consistent, localized therapy. By combining bronchodilation and anti-inflammatory action in one treatment, ensifentrine offers a differentiated and effective option for personalized respiratory care in adult COPD patients.